Clinical Trials – Page 11

AbbVie Acquires Rights to Ichnos Glenmark’s Lead Myeloma Antibody (ISB 2001) in $1.93 Billion Deal

4 months ago talkbio0Tagged AbbVie, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, CD3 Antigens, CD38 Antigen, Clinical Trials, Global Licensing, Ichnos Glenmark, ISB, Multiple Myeloma, Neoplasms, Phase 1 (qualifier value), Trispecific Antibody

AbbVie; Ichnos Glenmark; ISB 2001; trispecific antibody; multiple myeloma; biotech deal; CD3; BCMA; CD38; Phase 1 clinical trial; global licensing; oncology

Rhythm’s Oral MC4R Agonist Bivamelagon Shows Promising Results in Rare Obesity Type

4 months ago talkbio0Tagged Agonist, Bivamelagon, Body mass index procedure, Clinical Trials, Hypothalamic obesity, MC4R protein, human, oral weight loss drug, Rhythm

Rhythm Pharmaceuticals; oral weight-loss drug; bivamelagon; MC4R agonist; Phase 2 trial; hypothalamic obesity; BMI reduction; clinical trial results

Altimmune’s Incretin Misses Fibrosis Improvement Endpoints in MASH Trial

4 months ago talkbio0Tagged Altimmune, Clinical Trials, Fibrosis, Glucagon-Like Peptide 1, Incretins, MASH, pemvidutide

Altimmune; incretin; pemvidutide; fibrosis; MASH; GLP-1; clinical trial

TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects

4 months ago talkbio0Tagged Arcus Biosciences, Clinical Trials, Gilead, immuno-oncology, iTeos, Merck, Myers, Novartis, Pharma, Roche (company), SmithKline Beecham, squibb, TIGIT gene, Tiragolumab

TIGIT; immuno-oncology; failed clinical trials; pharma investment loss; Gilead; GSK; Bristol Myers Squibb; Novartis; Merck; Roche; iTeos; Arcus Biosciences; tiragolumab; belrestotug

Biogen Ushers Spinraza Follow-Up (Salanersen) Into Pivotal SMA Studies

4 months ago talkbio0Tagged Antistreptolysin O, Biogen, Clinical Trials, motor milestones, Nerve Degeneration, Novartis, Pediatric brand name, Phase III, salanersen, Spinal Muscular Atrophy, Spinraza, Zolgensma

Biogen; SMA; Spinraza; salanersen; Phase III; clinical trials; neurodegeneration; motor milestones; pediatric; Novartis Zolgensma; ASO therapy

Nektar Declares Phase IIb Eczema Win for Rezpeg, but Analysts Remain Skeptical

4 months ago talkbio0Tagged analysts, Clinical Trials, Dermatitis, Atopic, Dupixent, EASI, Eczema, Lilly partnership, Nektar Therapeutics, Phase II B Trial, Rezpeg, Rezpegaldesleukin, Score, Skepticism

Nektar Therapeutics; Rezpegaldesleukin; Rezpeg; Phase IIb trial; eczema; atopic dermatitis; clinical trial; EASI score; Dupixent; analyst skepticism; Lilly partnership

Leap Therapeutics Slashes 75% of Workforce, Ends Clinical Trial, Considers Strategic Options

4 months ago talkbio0Tagged Biotech Layoffs, Clinical Trials, FL-501, Flatulence, LEAP, Sirexatamab, strategic alternatives

Leap Therapeutics; workforce reduction; biotech layoffs; clinical trial; strategic alternatives; sirexatamab; FL-501; R&D wind down

Amgen Adjusts Phase 3 Dosing for MariTide After Midstage Side Effects Concerns

4 months ago talkbio0Tagged Adverse event, amgen, Clinical Trials, Dosage, Escalation, gastric inhibitory polypeptide receptor, GLP-1 receptor, MariTide, Obesity, Phase 3, Vomiting

Amgen; MariTide; Phase 3; obesity treatment; dose escalation; vomiting; adverse events; clinical trial; GLP-1 receptor; GIP receptor

BrightGene’s BGM0504 Outperforms Novo Nordisk’s Semaglutide in Diabetes Trial, Eyes Showdown with Zepbound

4 months ago talkbio0Tagged BGM0504, BrightGene, Clinical Trials, Diabetes, eli lilly, GLP-1/GIP receptor agonist, Glycosylated hemoglobin A, Nordisk, Obesity, semaglutide, Weight maintenance regimen, Zepbound

BrightGene; diabetes; GLP-1/GIP receptor agonist; BGM0504; semaglutide; Novo Nordisk; Eli Lilly; Zepbound; clinical trial; HbA1c reduction; obesity; weight management

Exelixis’ Zanzalintinib Achieves Key Survival Goal in Pivotal Colorectal Cancer Study

4 months ago talkbio0Tagged atezolizumab, checkpoint inhibitor, Clinical Trials, Colorectal Carcinoma, Exelixis, Overall Survival, STELLAR-303, Stivarga, zanzalintinib

Exelixis; zanzalintinib; colorectal cancer; pivotal trial; overall survival; atezolizumab; checkpoint inhibitor; Stivarga; STELLAR-303; clinical trial